kabutan

Kidswell Bio Corporation(4584) Summary

4584
TSE Growth
Kidswell Bio Corporation
222
JPY
-4
(-1.77%)
Dec 5, 12:50 pm JST
1.43
USD
Dec 4, 10:50 pm EST
Result
PTS
outside of trading hours
223
Dec 5, 12:50 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.16
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
222 JPY 1.43 USD
Previous Close Dec 4
226 JPY 1.45 USD
High Dec 5, 9:22 am
227 JPY 1.46 USD
Low Dec 5, 9:00 am
222 JPY 1.43 USD
Volume
383,200
Trading Value
0.09B JPY 0.55M USD
VWAP
223.74 JPY 1.44 USD
Minimum Trading Value
22,200 JPY 143 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
142
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
1,055
1-Year High Apr 15, 2025
10,934
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 4,805,700
Nov 21, 2025 0 5,316,200
Nov 14, 2025 0 5,197,300
Nov 7, 2025 0 5,475,000
Oct 31, 2025 0 5,411,900
Company Profile
Kidswell Bio Corporation is a drug discovery venture originating from Hokkaido University. The company focuses on biopharmaceuticals, biosimilars, antibody drugs, and pediatric medicines.
Sector
Pharmaceuticals
Kidswell Bio Corporation, a drug discovery venture born out of Hokkaido University, initially operated in three business areas: biopharmaceuticals, biosimilars, and cell therapy (regenerative medicine). However, to maximize corporate value and achieve rapid stock price recovery and growth, the company has shifted its strategy to concentrate management resources on the biosimilar business, which provides a stable revenue base, and the cell therapy business, which serves as a growth foundation. In the biosimilar business, the company has been involved in the development of four products, establishing a stable revenue base through sales of launched products. In the cell therapy business, Kidswell Bio is advancing the development of regenerative medicine products utilizing stem cells from deciduous tooth dental pulp (SHED). The company is responsible for manufacturing process development and active pharmaceutical ingredient supply in the biosimilar business, and covers from basic research to manufacturing in the cell therapy business. Both business segments emphasize partnerships with pharmaceutical companies, and the company is actively working to expand its operations.